arrow
R

Robert Redd

Dana-Farber Cancer Institute
H指数:39
被引数:9,671

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma

巨噬细胞重编程,而非CD8 T细胞动力学,是PD-1阻断后冒烟性骨髓瘤获得持久疾病控制的特点

Leukemia
IF13.4
2026-09-030
PRE
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study

达鲁珠单抗在高风险MGUS和低风险 smoldering myeloma 中的疗效:D-PRISM II期研究结果

2026-04-080
OAAI
Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin Lymphoma

新型疗法对移植后Brentuximab Vedotin维持治疗霍奇金淋巴瘤疗效的影响

2026-03-310
OAAI
Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma

整合单细胞生物物理和转录组特征以解析套细胞淋巴瘤的功能异质性

2025-12-050
OA
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure

基于先前CD19定向CAR T暴露的大B细胞淋巴瘤中Tafasitamab和Lenalidomide的治疗效果

2025-11-180
OAAI
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell Lymphoma

同步系统性及中枢神经系统弥漫大B细胞淋巴瘤的治疗与预后回顾性研究

2025-11-010
OAAI
Atorvastatin and Left Atrial Function During Anthracycline-based Chemotherapy

阿托伐他汀和他汀类化疗期间左心房功能

2025-08-260
OAAI
Measurable Residual Disease Detection after CAR-T May Predict Response in Patients with Large B-cell Lymphoma

CAR-T治疗后微小残留病检测可预测大B细胞淋巴瘤患者的治疗反应

2025-07-280
OAAI
First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer

首次人体评估:使用IL-15超激动剂和CTLA-4阻断治疗晚期头颈癌的记忆样NK细胞

2025-02-143
OA
Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma

癌症特异性的先天性和适应性免疫重构驱动经典霍奇金淋巴瘤对PD-1阻断的抵抗

2024-12-300
OA
Long-Term Follow-up of Bendamustine/Rituximab- Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

bendamustine/Rituximab- Rituximab/Cytarabine (BR/RC)诱导治疗对先前未治疗的移植符合条件的套细胞淋巴瘤(MCL)患者的长期随访

BLOOD
IF23.1
2024-11-050
PRE
Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

伊匹木单抗联合或不联合纳武利尤单抗治疗PD-1阻断治疗后进展的经典型霍奇金淋巴瘤患者

BLOOD
IF23.1
2024-11-050
PRE